TUCSON, Ariz., Nov. 4, 2019 /PRNewswire/ -- Accelerate
Diagnostics, Inc. (Nasdaq: AXDX) today announced that Roland Diggelmann has been appointed to its
Board of Directors.
"On behalf of the entire board, I am delighted to welcome Roland
to Accelerate Diagnostics," commented John
Patience, Chairman of the Board of Directors. "Roland brings
extensive experience from his decades of successful diagnostics
company leadership. We are especially excited about the counsel he
can provide to the management team, some of whom have worked with
him in the past at Roche."
Mr. Diggelmann was recently appointed Chief Executive Officer of
Smith+Nephew (NYSE:SNN) and has spent his entire career in the
medical technology and diagnostics industries. Prior to this
appointment, he served as CEO of Roche Diagnostics, a global
business with revenues of USD $11.5
billion and 34,000 employees at the time of his departure in
2018. Prior to his 11-year career at Roche Diagnostics, Roland
spent 12 years in the orthopedics sector at Sulzer Orthopedics and
Zimmer Group. Mr. Diggelmann studied Business Administration at the
University of Berne.
About Accelerate Diagnostics, Inc.
Accelerate
Diagnostics, Inc. is an in vitro diagnostics company
dedicated to providing solutions for the global challenges of
antibiotic resistance and sepsis. The Accelerate Pheno™ system and
Accelerate PhenoTest™ BC kit combine several technologies aimed at
reducing the time clinicians must wait to determine the most
optimal antibiotic therapy for deadly infections. The FDA cleared
system and kit fully automate the sample preparation steps to
report phenotypic antibiotic susceptibility results in
approximately 7 hours direct from positive blood cultures. Recent
external studies indicate the solution offers results 1-2 days
faster than existing methods, enabling clinicians to optimize
antibiotic selection and dosage specific to the individual patient
days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and
"ACCELERATE PHENOTEST" and diamond shaped logos and marks are
trademarks or registered trademarks of Accelerate Diagnostics,
Inc.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
Forward-Looking Statements
Certain of the
statements made in this press release are forward looking, such as
those, among others, about the company's projections as to when
certain key business milestones may be achieved, the potential of
the company's products or technology, the growth of the market, the
company's estimates as to the size of its market opportunity and
potential pricing, the company's competitive position and estimates
of time reduction to results, and its future development plans and
growth strategy. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Information about the risks and uncertainties faced
by Accelerate Diagnostics is contained in the section
captioned "Risk Factors" in the company's most recent Annual Report
on Form 10-K, filed with the Securities and Exchange
Commission on March 1, 2019, and in any other reports
that the company files with the Securities and Exchange
Commission. The company's forward-looking statements could be
affected by general industry and market conditions. Except as
required by federal securities laws, the company undertakes no
obligation to update or revise these forward-looking statements to
reflect new events, uncertainties or other contingencies.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accelerate-diagnostics-appoints-roland-diggelmann-to-its-board-of-directors-300950460.html
SOURCE Accelerate Diagnostics, Inc.